BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang J, Yang J, Li D, Li J. Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188454. [PMID: 33075468 DOI: 10.1016/j.bbcan.2020.188454] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Xu XJ, Gao HX, Zhu LC, Zhu R. Identifying Tumor-Associated Genes from Bilayer Networks of DNA Methylation Sites and RNAs. Life (Basel) 2022;13. [PMID: 36676027 DOI: 10.3390/life13010076] [Reference Citation Analysis]
2 Guan Z, Luo L, Liu S, Guan Z, Zhang Q, Wu Z, Tao K. The role of TGR5 as an onco-immunological biomarker in tumor staging and prognosis by encompassing the tumor microenvironment. Front Oncol 2022;12:953091. [DOI: 10.3389/fonc.2022.953091] [Reference Citation Analysis]
3 Song D, Zhou Z, Wu J, Wei T, Zhao G, Ren H, Zhang B. DNA methylation regulators-related molecular patterns and tumor immune landscape in hepatocellular carcinoma. Front Oncol 2022;12:877817. [DOI: 10.3389/fonc.2022.877817] [Reference Citation Analysis]
4 Liu K, Cui L, Li C, Tang C, Niu Y, Hao J, Bu Y, Chen B. Pan-cancer analysis of the prognostic and immunological role of ANLN: An onco-immunological biomarker. Front Genet 2022;13:922472. [DOI: 10.3389/fgene.2022.922472] [Reference Citation Analysis]
5 Wang J, Li D, Yang J, Chang L, Zhang R, Li J. CRISPR/Cas9-mediated epigenetic editing tool: An optimized strategy for targeting de novo DNA methylation with stable status via homology directed repair pathway. Biochimie 2022. [DOI: 10.1016/j.biochi.2022.07.013] [Reference Citation Analysis]
6 Zhang S, Duan S, Xie Z, Bao W, Xu B, Yang W, Zhou L. Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress. Front Pharmacol 2022;13:924817. [PMID: 35754474 DOI: 10.3389/fphar.2022.924817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shojaei Baghini S, Gardanova ZR, Abadi SAH, Zaman BA, İlhan A, Shomali N, Adili A, Moghaddar R, Yaseri AF. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool. Cell Mol Biol Lett 2022;27:35. [PMID: 35508982 DOI: 10.1186/s11658-022-00336-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Luo JF, Yao YD, Cheng CS, Lio CK, Liu JX, Huang YF, He F, Xie Y, Liu L, Liu ZQ, Zhou H. Sinomenine increases the methylation level at specific GCG site in mPGES-1 promoter to facilitate its specific inhibitory effect on mPGES-1. Biochim Biophys Acta Gene Regul Mech 2022;1865:194813. [PMID: 35417776 DOI: 10.1016/j.bbagrm.2022.194813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liu J, Yao S, Jia J, Chen Z, Yuan Y, He Y, Wasti B, Duan W, Li D, Wang G, Jia A, Sun W, Qiu S, Ma L, Li J, Liu Y, Zheng J, Xiang X, Zhang X, Liu S, He Z, Peng Z, Zhang H, Zhang D, Xiao B. Loss of MBD2 ameliorates LPS‐induced alveolar epithelial cell apoptosis and ALI in mice via modulating intracellular zinc homeostasis. The FASEB Journal 2022;36. [DOI: 10.1096/fj.202100924rr] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Pan W, Wang K, Li J, Li H, Cai Y, Zhang M, Wang A, Wu Y, Gao W, Weng W. Restoring HOXD10 Exhibits Therapeutic Potential for Ameliorating Malignant Progression and 5-Fluorouracil Resistance in Colorectal Cancer. Front Oncol 2021;11:771528. [PMID: 34790580 DOI: 10.3389/fonc.2021.771528] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Xu Y, Yu X, Zhang M, Zheng Q, Sun Z, He Y, Guo W. Promising Advances in LINC01116 Related to Cancer. Front Cell Dev Biol 2021;9:736927. [PMID: 34722518 DOI: 10.3389/fcell.2021.736927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chen X, Lu Y, Yu H, Du K, Zhang Y, Nan Y, Huang Q. Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene. Cell Cycle 2021;20:2291-308. [PMID: 34585645 DOI: 10.1080/15384101.2021.1982494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Chan DW, Lam WY, Chen F, Yung MMH, Chan YS, Chan WS, He F, Liu SS, Chan KKL, Li B, Ngan HYS. Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. Clin Epigenetics 2021;13:142. [PMID: 34294135 DOI: 10.1186/s13148-021-01130-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhong GC, Zhao ZB, Cheng Y, Wang YB, Qiu C, Mao LH, Hu JJ, Cai D, Liu Y, Gong JP, Li SW. Epigenetic silencing of GCH1promotes hepatocellular carcinoma growth by activating superoxide anion-mediated ASK1/p38 signaling via inhibiting tetrahydrobiopterin de novo biosynthesis. Free Radic Biol Med 2021;168:81-94. [PMID: 33781891 DOI: 10.1016/j.freeradbiomed.2021.03.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]